Encyclopedia · antiandrogen
GT20029
A topical drug that tags the androgen receptor for destruction instead of just blocking it; a 12-week phase 2 in Chinese men showed modest gains.
What it is
GT20029 is a topical androgen receptor degrader from Suzhou Kintor. A 2025 review describes it as one of the first topical PROTACs in clinical trials, alongside AH-001, both for male pattern hair loss. Gioiello 2025 It is investigational, not approved and not for sale.
What the studies show
- Phase 2 (180 Chinese men, 12 weeks, double-blind): GT20029 0.5% or 1.0%, once daily or twice weekly, vs placebo. Hair count rose in all four active groups; 0.5% daily and 1.0% twice weekly beat their placebo (p = 0.032 and 0.023), and hair width improved for 1.0% twice weekly (p = 0.011). Adverse events were mild and similar across groups. Hu 2025
Side effects and safety
Effects were mild and similar to placebo over 12 weeks. We found no long-term or body-wide hormone data.
Bottom line
One 12-week phase 2 is short, and not every dose arm beat placebo. The technology is interesting but years from the clinic. Discuss with a doctor.
Fun facts
- Degrading the receptor rather than blocking it is the strategy now used in some cancer drugs, adapted here for scalp skin. Gioiello 2025
Studies 2
Hu R et al. Topical GT20029 in male androgenetic alopecia: phase 2. J Dermatolog Treat. 2025
Tested: GT20029 0.5% or 1.0%, once daily or twice weekly, vs placebo
Result: Hair count rose in all four active groups; 0.5% daily and 1.0% twice weekly beat their placebo (p = 0.032, p = 0.023); hair width improved for 1.0% twice weekly (p = 0.011); adverse events were mild and similar across groups.
Read the study ↗Gioiello L et al. Expanding the scope of PROTACs: topical delivery. J Med Chem. 2025
Tested: review
Result: Describes GT20029 and AH-001 as among the first topical PROTACs in clinical trials for androgenetic alopecia.
Read the study ↗Related
- PyrilutamideA topical androgen blocker from the Chinese company Kintor that reported positive pivotal results in China; no peer-reviewed efficacy paper yet.
- ClascoteroneA topical androgen blocker already approved as an acne cream whose 5% scalp solution reported positive phase 3 results in men; it is not yet approved for hair.
- Antiandrogen comparison for hair lossA side-by-side of the drugs, topicals and supplements that work on the androgen pathway, with who they were studied in and how strong the evidence is.